Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

Presented By
Prof. Solange Peters, Lausanne University, Switzerland
Conference
WCLC 2022
Trial
Phase 3, POSEIDON
Doi
https://doi.org/10.55788/b24ddb43
An exploratory analysis of the phase 3 POSEIDON trial showed that first-line treatment with tremelimumab plus durvalumab plus chemotherapy was efficacious in subgroups of patients with metastatic non-small cell lung cancer (NSCLC) that are usually associated with poor responses to immunotherapy, including those with KEAP1, KRAS, and STK11 mutations [1]. In patients with EGFR/ALK wildtype metastatic NSCLC, the combination of tremelimumab, durvalumab, and chemotherapy outperformed chemotherapy alone regarding progression-free survival (PFS) and overall survival (OS), primary results from the phase 3 POSEIDON trial (NCT03164616) displayed (n=1,003) [2]. However, it was unknown whether this combination treatment was beneficial for patients with STK11, KEAP1, or KRAS mutations. Therefore, Prof. Sola...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on